Media Coverage
Article in the Australian newspaper, Monday November 16 200917 Nov 2009 Dear Shareholder or follower of Compumedics As the Company has noted in previous correspondence it is pursuing distinct growth paths for its core diagnostic business and its Medical Innovation Division break-out technologies, the latter including its sleep-treatment technology. The article appearing in the Australian newspaper (attached) on 16th November 2009 was focused on the opportunity for the Company’s new sleep-treatment technology and device – the SomniLink® SPAP®. In relation to the sleep-treatment technology, the Company has been, and will continue, pursuing all logical and appropriate opportunities to enable the SomniLink® SPAP® sleep-treatment device to achieve its full commercial potential. Parallel to these activities, the Company continues to focus on, and invest in, the organic and other growth options for its existing core medical diagnostic device business. This business incorporates the Company’s sleep diagnostic device business as well as neurological monitoring devices (including brain research devices) and the ultrasonic blood-flow business. The Company will continue to up-date you and the market more generally as material matters arise and provide the up-date and article for your information. To read the online version of this article Click here To see the article in PDF format Click here (118 KB) 
For Further information: Mr David Burton Mr David Lawson
Executive Chairman, CEO Chief Financial Officer
Phone: + 61 3 8420 7300 Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399 Fax: +61 3 8420 7399 Investor Relations & Media Enquires: Mr Rod North
Managing Director
Bourse Communications Pty Ltd
Phone: +61 3 9510 8309
Mobile: +61 (0) 408 670 706 About Compumedics Compumedics Limited, founded in 1987, is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In 1987 Compumedics established Asia Pacific’s first fully computerised sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological, and Doppler blood-flow diagnostic monitoring devices. In 1995 the company was selected to supply equipment to the US Sleep Heart Health Study, the world’s largest sleep study of its kind, currently exceeding 14,000 studies with 20,000 patients scheduled by 2008. With headquarters in Melbourne, Australia and offices in the United States, and Europe the products are distributed in over 50 countries. In 1998 Compumedics was awarded the overall Australian Exporter of the Year. In 2000 Compumedics was listed on the Australian Stock Exchange. In 2002, Compumedics acquired US-based Neuroscan - the world's leading supplier of instruments for brain-research. In the US - the world's largest medical device market - Neuroscan holds around 90% of the market for brain-research products. In 2003 Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy. In 2004, Compumedics acquired German-based DWL Elektronishe GmbH, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. In 2006, Compumedics was awarded the Frost and Sullivan Technology Leadership award for the innovative Somté recorder product. In 2007, Compumedics and Chairman were inducted into the Victorian Manufacturing Hall of Fame. In 2008 the DWL division received the top 100 German Innovation award. With 20,000 systems installed globally across the finest hospital, universities and clinics the Compumedics sales have grown more than 4 fold from $9 million (1999) to $39 million (2008). In 2009 Compumedics was awarded a design award for its Grael™ PSG/EEG premium laboratory based product. Viait : www.compumedics.com for more information  Back
|
